Physician profile
Narpinder Singh
NPI 1518039791
$1,665.09
in general payments reported to CMS, 2019-2025
14 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $272 · 2021: $183 · 2022: $351 · 2023: $94.10 · 2024: $69.36 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $570.07 | 2019-2025 | Eliquis |
| Pfizer INC. | $211.00 | 2019-2025 | |
| Edwards Lifesciences Corporation | $182.08 | 2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $169.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.00 | 2022 | |
| Lilly USA, LLC | $124.00 | 2025 | |
| Chiesi USA, INC. | $83.64 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.63 | 2024-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $35.64 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.73 | 2019-2025 | Jardiance |
| Lantheus Medical Imaging, INC. | $23.61 | 2025 | |
| Abbott Laboratories | $23.05 | 2022 | |
| Medtronic, INC. | $20.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.35 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narpinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.